VINC breaking out soon?

Very little to be found on this one fundamentally, as to what the catalyst could be.
But SEC forms show numerous insiders (including CEO) buying before Christmas. Today, analyst Geulah Livshits from Chardan Capital released a buy rating with a PT of 33.
biomedFundamental AnalysisPHARMA

Pernyataan Penyangkalan